Solstice Advanced Materials (SOLS) Q1 2026 earnings review
Top-Line Accelerates on Secular Tailwinds, but Standalone Costs Bite
Solstice delivered a strong first quarter as an independent company, with revenue growth accelerating to 10% YoY. The top-line beat was fueled by secular megatrends: nuclear energy, AI/semiconductor materials, and data center cooling. However, profitability tells a more complicated story. Net Income plunged 37% YoY as the company absorbed $52 million in standalone corporate expenses following its spin-off from Honeywell, and a product mix shift compressed margins in its largest segment. Management reaffirmed FY26 guidance, expecting margins to stabilize in the second half of the year.
🐂 Bull Case
Solstice is perfectly positioned for current macro tailwinds. Nuclear revenues surged 27%, Electronic Materials jumped 21% on AI chip demand, and Refrigerants grew 19%.
Adjusted EBITDA growth stabilized at 0% YoY in Q1, a stark reversal from the 28% contraction in 25Q4. With transitory spin-off costs fading, Q2 guidance implies a sequential margin expansion to 25-26%.
🐻 Bear Case
The Refrigerants & Applied Solutions (RAS) segment drives ~80% of total EBITDA, but its margin plummeted 522 bps YoY to 34.1%. The transition to low global warming potential (LGWP) refrigerants is actively diluting profitability.
Corporate expenses spiked from $32M to $52M YoY. If this is the new run-rate for operating as a standalone public company, the bridge to meaningful Net Income growth will be longer than anticipated.
⚖️ Verdict: ⚪
Neutral. The revenue acceleration across key future-facing segments is highly encouraging, but the structural margin dilution from the LGWP transition and elevated corporate overhead cap near-term upside.
Key Themes
RAS Margin Headwinds Contradict Top-Line Strength
A major concern emerged in the Refrigerants & Applied Solutions (RAS) segment. Despite robust 12% revenue growth driven by strong volume and pricing, segment Adjusted EBITDA actually declined 3% YoY. The EBITDA margin collapsed by 522 basis points to 34.1%. Management attributes this to the ongoing transition from legacy HFCs to low global warming potential (LGWP) refrigerants, which carry lower initial margins, alongside higher R&D spend. This structural mix shift limits operating leverage during a period of high demand.
Nuclear Renaissance Accelerating
Alternative Energy Services (Nuclear) sales accelerated to 27% YoY growth ($107 million). As the operator of the only uranium hexafluoride (UF6) conversion facility in the U.S. (Metropolis Works), Solstice is directly capitalizing on the global resurgence in nuclear energy. With a backlog exceeding $2 billion stretching through 2030, this segment offers exceptional forward visibility.
Electronic Materials Riding the AI Wave
Electronic Materials revenue grew a staggering 21% YoY to $109 million. The driver is robust customer demand for deposition and thermal solutions used in leading-edge applications, specifically sub-7nm semiconductor chips required for AI and data centers. This volume growth pushed the broader ESM segment's Adjusted EBITDA up 10% YoY, proving strong flow-through to the bottom line.
The Cost of Independence
Net Income fell 37% YoY to $85 million, fundamentally disconnected from the 10% revenue growth. The primary culprit is a $20 million YoY spike in Corporate Expenses (reaching $52 million in Q1), representing the incremental, ongoing costs necessary to operate as an independent public company post-Honeywell spin-off. Add in higher net interest expense on $2.0B of long-term debt, and the bottom line is structurally heavier.
Destocking Reverses in Healthcare Packaging
Reversing a brutal trend from 2025 (where Q4 revenues plummeted 25%), Healthcare Packaging sales rebounded to 9% growth YoY. Management confirmed that customer destocking in the pharmaceutical end-market has concluded, normalizing order patterns and restoring plant absorption rates.
Macro Softness in Construction
While tech and energy segments thrive, traditional end-markets are struggling. Building Solutions & Intermediates sales decelerated by 8% YoY to $167 million. The company cited ongoing end-market softness in construction, highlighting macroeconomic vulnerability in this cyclical division.
Innovation in Next-Gen Molecules
R&D expense increased roughly 27% YoY (from $22M to $28M). Solstice is heavily investing in the development of next-generation molecules to support the LGWP refrigerant transition and advanced semiconductor packaging. While depressing current margins, this pipeline is critical for protecting the company's massive 5,700+ patent portfolio and future pricing power.
Other KPIs
Stable cash generation despite elevated capital expenditures ($82M, +32% YoY) aimed at long-term capacity expansion. The solid cash profile easily covers the newly initiated $0.075 per share quarterly dividend (requiring ~$12M) and supports a comfortable 1.4x Net Leverage ratio.
Stable at 0% YoY growth. Growth in personal care products was perfectly offset by ongoing weakness in construction end-markets. A lack of volume growth here places the burden of ESM segment expansion entirely on Electronic Materials.
Guidance
Accelerating. The midpoint of $1.08 billion implies strong sequential momentum from Q1's $991 million, indicating confidence that destocking has ended and secular tailwinds (Nuclear, AI) will continue to compound.
Stable. The midpoint of 25.5% represents a sequential improvement from Q1's 25.1%, suggesting that management expects to maintain pricing discipline and slightly better operating leverage as volume ramps up.
Stable. Reaffirmed guidance. The midpoint ($4.0B) implies roughly 0.5% growth over FY25's $3.98B. However, given the $30M one-time revenue headwind from a nuclear loan repayment expected this year, underlying organic growth expectations are higher.
Stable. Reaffirmed guidance. The midpoint ($1.0B) implies ~4.5% growth over FY25's Adjusted Standalone EBITDA of $957M, reinforcing management's view that transitory headwinds will clear in the back half of the year.
Key Questions
Corporate Run-Rate Validation
Corporate expenses hit $52M this quarter, up from $32M a year ago. Is this $52M the normalized run-rate for operating as a standalone entity, or are there lingering transition redundancies that will roll off?
HFO Aftermarket Timing
With the LGWP transition aggressively diluting RAS margins, when exactly does management expect the higher-margin HFO aftermarket to achieve sufficient scale to make this product line margin-accretive?
Metropolis Expansion Timeline
Nuclear revenue is surging, and the backlog sits above $2B. Can you provide an update on the Department of Energy cost-sharing agreement and the specific timeline for breaking ground on the Metropolis capacity expansion?
Construction Rebound
Building Solutions remains a drag on top-line growth. What specific macro indicators (e.g., rate cuts, housing starts) are you tracking to signal a bottom in this end-market?